PROPRIETARY AND CONFIDENTIALHere are just a few key highlights from Wave I:Summary of findingsTreatments & Efficacy:•3 most commonly prescribed treatments amongst COVID-19 treaters are 56% analgesics, 41% Azithromycin, and 33% Hydroxychloroquine.•Hydroxychloroquine usage amongst COVID-19 treatersis 72% in Spain, 49% in Italy, 41% in Brazil, 39% in Mexico, 28% in France, 23% in US, 17% in Germany, 16% in Canada, 13% in UK and 7% in Japan.•Hydroxychloroquine was overall chosen as the most effective therapy from a list of 15 options (37% of COVID-19 treaters).•75% in Spain, 53% Italy, 44% in China, 43% in Brazil, 29% in France, 23% in US and 13% in UK.•The two most common treatment regimens for Hydroxychloroquine were:•(38%) 400mg twice daily on day one; 400 mg daily for 5 days.•(26%) 400mg twice daily on day one; 200mg twice daily for 4 days.•Outside the US, Hydroxychloroquine was equally used for diagnosed patients with mild to severe symptoms whereas in the US it wasmost commonly used for high risk diagnosed patients.•Globally, 19% of physicians prescribed or have seen Hydroxychloroquine prophylactically used for high risk patients, and 8% for low risk patients.
The USA is actually behind the curve in using HCQ 
|
